SlideShare a Scribd company logo
1 of 1
Retrospective Study 2008 Norovirus Outbreak in LTC  Gillian Jones MBA MPH; Tae Joon Lee, MD, CMD  UMC-IRB # 09-0250   Conflict of Interest:  The investigators affiliated with both the university and the  subject long term care facility, however retained full independence in the conduct of this study.   AMDA Poster abstract  # 513 References Abstract Setting:   This 16 day acute gastroenteritis outbreak began December 29, 2008 in a 152-bed Medicaid/Medicare certified detached for-profit nursing home facility in eastern North Carolina.  The midsized free standing for-profit facility has two nursing stations with six halls. See floor plan below.  Retrospective epidemiologic investigation:  Facility approval and East Carolina University Internal Review Board approval for exempt study status was granted on March 18, 2009.  Discharged and current patient data from medical charts and supporting related documents were reviewed.  Also interviewed were local health department (LHD), state health department (SHD), and D), key NH staff, and a sampling of infected staff.  Key facility personnel were interviewed to gather pertinent patient care costs and facility revenue and outbreak related expenditures and costs. AGE Case definition:  A case was defined as a patient or employee with onset of vomitus and/or diarrheal symptoms with vomiting or diarrhea, two or more loose stools in a minimum two gastro-intestinal episodes in a twenty four hour period with onset during December 29, 2008-January 15, 2009 in a resident or employee of the nursing home during the outbreak period. To prevent possible misclassification, exclusions included a history of recent loose stool or gastrointestinal diagnosis in the last 30 days,  and/or use of antibiotics during the outbreak.  Analysis:   A variety of analyses were performed on 125 patients with complete records including.  Analyses included simple descriptive, t-tests, non-parametric tests for medians, chi-square tests, and multivariate logistic regression using a combination of using  JMP 9 and PASW v17 (REFS ) software.  Epidemiologic curves were generated with GOATv2.1/EpiInfo software. Costs summarized on Excel software.  ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Methods OBJECTIVES:  1. Perform retrospective descriptive epidemiologic study of lab confirmed Noro-virus (NV) outbreak in a midsized North Carolina detached nursing home (NH) 2. Examine and compare acute gastroenteritis (AGE) outbreak characteristics and patient risk factors in NV transmission 3.  Describe the infection control measures implemented by the NH and the local health department 4.  Examine  NV outbreak cost to NH.  METHODS:  Epidemiological data were collected retrospectively and results compared to other individual long term care facility NV outbreaks as well as compared to 1982 Kaplan criteria for NV diagnosis. Outbreak control methods and costs were assessed and compared.  RESULTS:  A NV outbreak duration of 16 days with 2.5 median symptomatic days affected 71 patient cases (56.8 %) and 24 staff cases (19.8%) with symptoms of acute gastroenteritis.  NV strain geno group type II confirmed. 11 patients required in-house oral and IV rehydration, 6 patients required hospital evaluation and care, and 1 patient with multiple co-morbidities died.  Risk factors (as measured by adjusted odds ratios) for NV infection include females (OR 3.39; p=0.006), diabetes mellitus (OR 2.76; p=0.031), and Activities of Daily Living (ADL) Dependency index score of less than 5 (OR 7.18; p = 0.04). Outbreak cost incurred to NH estimated to be $34,000.  CONCLUSIONS:  Group II NV outbreak likely spread via person-to-person contact. Multi-disciplinary enhanced hygiene measures, staff self-quarantine, and admissions/visitors ban may have lessened duration and severity.  Implementation of control measures should not wait for reference lab viral identification of specimens.  Table 3:  CDC Reporting and NV Identification  Figure 1. Onset Curve by Date Table 1:  Outbreak Characteristics  Table 2:  NV Risk Factors (unadjusted odds ratio)  ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],UNIT II Station UNIT I Station Symptom  No symptom OR (95% interval) p-value     n=71 (%) n=54 (%) Female*     61 (85.9) 36 (66.7) 3.39 (1.38-8.33) 0.006 Caucasian    28 (39.4) 24 (44.4) 1.23 (0.59-2.52) 0.57 Sick Roommate  39 (54.9) 24 (44.4) 1.52 (0.75-3.1) 0.25 Private Room 11 (15.5) 4 (7.4) 2.29 (0.69-7.64) 0.17 Unit I   47 (66.2) 27 (50.0) 1.95 (0.94-4.05) 0.068 Unit II   25 (35.2) 27 (50.0) 0.54 (0.26-1.12) 0.097 Diabetes*   29 (40.9) 7 (13.0) 2.76 (1.07-7.1) 0.031 ALZ/Dementia  27 (38.0) 13 (24.1) 1.89 (0.86-4.15) 0.11 Renal Failure/ 7 (9.9) 6 (11.1) 0.84 (0.26-2.66) 0.76 Kidney Disease CVD/CVA   13 (18.3) 12 (22.2) 0.77 (0.32-1.85) 0.55 HTN   19 (26.8) 14 (25.9) 1.02 (0.45-2.28) 0.97 HD/CHF   13 (18.3) 13 (24.1) 0.69 (0.29-1.64) 0.40 Other DX   31 (43.7) 19 (35.2) 1.39 (0.67-2.88) 0.38 ADL Score < 5  8 (11.3) 1 (1.9) 7.18 (1.01-59.38) 0.042 * Statistically significant findings Jan 2, 2009 Day 5  Clinical  outbreak protocol  begins Jan 5, 2009 Day 8  Ban on ad-missions & transfers begins NV lab confirmed Enhanced  hygiene measures begun  Jan 11, 2009 Day 14 Last new case reported.  Discussion 2008 NV LTC OUTBREAK – animated infection transmission  video:  To view the internet video of an animated room by room time lapsed infection sequence showing rate and pattern of spread please enter the following hyperlink. The sequence repeats several times. and will play automatically on Windows media player.  http://personal.ecu.edu/brinkleyjresearch/outbreak.avi Table 4:  Infection Control & Prevention Measures  Dec 29, 2008 Day 1 Index case reported  NURSING HOMES 30% of 1996-2000 Reported GE Outbreaks   Results ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Figure 2. Facility Floor plan NV infected cases State reference lab confirmed NV cases Asymptomatic residents ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Clinical Measures Administrative Measures Local Health Department ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

More Related Content

What's hot

Factors Related to HCV Screening in French General Practice
Factors Related to HCV Screening in French General PracticeFactors Related to HCV Screening in French General Practice
Factors Related to HCV Screening in French General PracticeMichel Rotily
 
Hepatitis C virus infection and type 2 diabetes mellitus in Mexican patients.
Hepatitis C virus infection and type 2 diabetes mellitus in Mexican patients. Hepatitis C virus infection and type 2 diabetes mellitus in Mexican patients.
Hepatitis C virus infection and type 2 diabetes mellitus in Mexican patients. Erwin Chiquete, MD, PhD
 
Start impaact june 7 2011
Start impaact june 7 2011Start impaact june 7 2011
Start impaact june 7 2011Phil Boehmer
 
Clinical presentation and outcomes of HIV positive patients with diagnosis of...
Clinical presentation and outcomes of HIV positive patients with diagnosis of...Clinical presentation and outcomes of HIV positive patients with diagnosis of...
Clinical presentation and outcomes of HIV positive patients with diagnosis of...Oscar Malpartida-Tabuchi
 
Journal club edgt 2016 (1)
Journal club edgt 2016 (1)Journal club edgt 2016 (1)
Journal club edgt 2016 (1)sath_gasclub
 
Feb 2015 journal watch with links
Feb 2015 journal watch with linksFeb 2015 journal watch with links
Feb 2015 journal watch with linkskatejohnpunag
 
Acg guideline cdifficile_april_2013
Acg guideline cdifficile_april_2013Acg guideline cdifficile_april_2013
Acg guideline cdifficile_april_2013cesar gaytan
 
A trial of Lopinavir-Ritonavir in Adults Hospitalized with Sever COVID-19
A trial of Lopinavir-Ritonavir in Adults Hospitalized with Sever COVID-19A trial of Lopinavir-Ritonavir in Adults Hospitalized with Sever COVID-19
A trial of Lopinavir-Ritonavir in Adults Hospitalized with Sever COVID-19Valentina Corona
 
Antinuclear antibody positivity in chronic hepatitis c patients
Antinuclear antibody positivity  in chronic hepatitis c patientsAntinuclear antibody positivity  in chronic hepatitis c patients
Antinuclear antibody positivity in chronic hepatitis c patientsRashed Hassen
 
Pie diabetico guia 2012
Pie diabetico guia 2012Pie diabetico guia 2012
Pie diabetico guia 2012Residentes1hun
 

What's hot (20)

Factors Related to HCV Screening in French General Practice
Factors Related to HCV Screening in French General PracticeFactors Related to HCV Screening in French General Practice
Factors Related to HCV Screening in French General Practice
 
Hepatitis C virus infection and type 2 diabetes mellitus in Mexican patients.
Hepatitis C virus infection and type 2 diabetes mellitus in Mexican patients. Hepatitis C virus infection and type 2 diabetes mellitus in Mexican patients.
Hepatitis C virus infection and type 2 diabetes mellitus in Mexican patients.
 
Start impaact june 7 2011
Start impaact june 7 2011Start impaact june 7 2011
Start impaact june 7 2011
 
doi: 10.1101/2021.05.28.21258012
doi: 10.1101/2021.05.28.21258012doi: 10.1101/2021.05.28.21258012
doi: 10.1101/2021.05.28.21258012
 
Mr t2 candida
Mr t2 candidaMr t2 candida
Mr t2 candida
 
Clinical presentation and outcomes of HIV positive patients with diagnosis of...
Clinical presentation and outcomes of HIV positive patients with diagnosis of...Clinical presentation and outcomes of HIV positive patients with diagnosis of...
Clinical presentation and outcomes of HIV positive patients with diagnosis of...
 
CROI 2015 FINAL
CROI 2015 FINALCROI 2015 FINAL
CROI 2015 FINAL
 
Nov journal watch
Nov journal watchNov journal watch
Nov journal watch
 
Sepsis Guidelines 2016-2017
Sepsis Guidelines 2016-2017Sepsis Guidelines 2016-2017
Sepsis Guidelines 2016-2017
 
Journal club edgt 2016 (1)
Journal club edgt 2016 (1)Journal club edgt 2016 (1)
Journal club edgt 2016 (1)
 
Nia (1)
Nia (1)Nia (1)
Nia (1)
 
Feb 2015 journal watch with links
Feb 2015 journal watch with linksFeb 2015 journal watch with links
Feb 2015 journal watch with links
 
Acute pancreatitis
Acute pancreatitisAcute pancreatitis
Acute pancreatitis
 
Acg guideline cdifficile_april_2013
Acg guideline cdifficile_april_2013Acg guideline cdifficile_april_2013
Acg guideline cdifficile_april_2013
 
EXPANSION 2016
EXPANSION 2016EXPANSION 2016
EXPANSION 2016
 
EXPANSION 2016
EXPANSION 2016EXPANSION 2016
EXPANSION 2016
 
A trial of Lopinavir-Ritonavir in Adults Hospitalized with Sever COVID-19
A trial of Lopinavir-Ritonavir in Adults Hospitalized with Sever COVID-19A trial of Lopinavir-Ritonavir in Adults Hospitalized with Sever COVID-19
A trial of Lopinavir-Ritonavir in Adults Hospitalized with Sever COVID-19
 
1. clinical prediction rule for hcv
1. clinical prediction rule for hcv1. clinical prediction rule for hcv
1. clinical prediction rule for hcv
 
Antinuclear antibody positivity in chronic hepatitis c patients
Antinuclear antibody positivity  in chronic hepatitis c patientsAntinuclear antibody positivity  in chronic hepatitis c patients
Antinuclear antibody positivity in chronic hepatitis c patients
 
Pie diabetico guia 2012
Pie diabetico guia 2012Pie diabetico guia 2012
Pie diabetico guia 2012
 

Similar to 3.10 Nv Poster Draft

Fletcher et al-2013-pediatric_blood_&amp;_cancer
Fletcher et al-2013-pediatric_blood_&amp;_cancerFletcher et al-2013-pediatric_blood_&amp;_cancer
Fletcher et al-2013-pediatric_blood_&amp;_cancermayagomez7
 
Fletcher et al-2013-pediatric_blood_&amp;_cancer
Fletcher et al-2013-pediatric_blood_&amp;_cancerFletcher et al-2013-pediatric_blood_&amp;_cancer
Fletcher et al-2013-pediatric_blood_&amp;_cancerisabelerazochaves
 
G Js Poster Amda Abstract
G Js Poster Amda AbstractG Js Poster Amda Abstract
G Js Poster Amda Abstractgillian1007
 
2.1.11template For Nv Slide Show
2.1.11template For Nv Slide Show2.1.11template For Nv Slide Show
2.1.11template For Nv Slide Showgillian1007
 
An AIDS-Defining Illness Presenting during Acute Retroviral Syndrome: A Case ...
An AIDS-Defining Illness Presenting during Acute Retroviral Syndrome: A Case ...An AIDS-Defining Illness Presenting during Acute Retroviral Syndrome: A Case ...
An AIDS-Defining Illness Presenting during Acute Retroviral Syndrome: A Case ...UC San Diego AntiViral Research Center
 
Start impaact june 7 2011
Start impaact june 7 2011Start impaact june 7 2011
Start impaact june 7 2011Phil Boehmer
 
Deteriorating Patient with Sepsis: Early Diagnosis and Intervention (2017)
Deteriorating Patient with Sepsis: Early Diagnosis and Intervention (2017)Deteriorating Patient with Sepsis: Early Diagnosis and Intervention (2017)
Deteriorating Patient with Sepsis: Early Diagnosis and Intervention (2017)Arete-Zoe, LLC
 
Applied Epid
Applied EpidApplied Epid
Applied Epidhoneygbee
 
The value of real-world evidence for clinicians and clinical researchers in t...
The value of real-world evidence for clinicians and clinical researchers in t...The value of real-world evidence for clinicians and clinical researchers in t...
The value of real-world evidence for clinicians and clinical researchers in t...Arete-Zoe, LLC
 
Presentació resultats Estudi multicèntric amb telemedicina Red Promete per pa...
Presentació resultats Estudi multicèntric amb telemedicina Red Promete per pa...Presentació resultats Estudi multicèntric amb telemedicina Red Promete per pa...
Presentació resultats Estudi multicèntric amb telemedicina Red Promete per pa...brnmomentum
 
Telemedicine: Maintaining The Control and Clinical Outcomes During COVID-19 P...
Telemedicine: Maintaining The Control and Clinical Outcomes During COVID-19 P...Telemedicine: Maintaining The Control and Clinical Outcomes During COVID-19 P...
Telemedicine: Maintaining The Control and Clinical Outcomes During COVID-19 P...semualkaira
 
Telemedicine: Maintaining The Control and Clinical Outcomes During COVID-19 P...
Telemedicine: Maintaining The Control and Clinical Outcomes During COVID-19 P...Telemedicine: Maintaining The Control and Clinical Outcomes During COVID-19 P...
Telemedicine: Maintaining The Control and Clinical Outcomes During COVID-19 P...semualkaira
 
Early HIV Intervention by Dr. Rachel Baden
Early HIV Intervention by Dr. Rachel BadenEarly HIV Intervention by Dr. Rachel Baden
Early HIV Intervention by Dr. Rachel BadenSearch For A Cure
 
Assessing the effects of prognostic factors in recovery of tuberculosis patie...
Assessing the effects of prognostic factors in recovery of tuberculosis patie...Assessing the effects of prognostic factors in recovery of tuberculosis patie...
Assessing the effects of prognostic factors in recovery of tuberculosis patie...Alexander Decker
 
Adverse effects of delayed antimicrobial treatment and surgical source contro...
Adverse effects of delayed antimicrobial treatment and surgical source contro...Adverse effects of delayed antimicrobial treatment and surgical source contro...
Adverse effects of delayed antimicrobial treatment and surgical source contro...Manuel Pivaral
 
Risk factors of chronic liver disease amongst patients receiving care in a Ga...
Risk factors of chronic liver disease amongst patients receiving care in a Ga...Risk factors of chronic liver disease amongst patients receiving care in a Ga...
Risk factors of chronic liver disease amongst patients receiving care in a Ga...iosrjce
 
Four Unique Laboratory Characteristics Applied to Assess the Severity of COVI...
Four Unique Laboratory Characteristics Applied to Assess the Severity of COVI...Four Unique Laboratory Characteristics Applied to Assess the Severity of COVI...
Four Unique Laboratory Characteristics Applied to Assess the Severity of COVI...semualkaira
 
Four Unique Laboratory Characteristics Applied to Assess the Severity of COVI...
Four Unique Laboratory Characteristics Applied to Assess the Severity of COVI...Four Unique Laboratory Characteristics Applied to Assess the Severity of COVI...
Four Unique Laboratory Characteristics Applied to Assess the Severity of COVI...komalicarol
 

Similar to 3.10 Nv Poster Draft (20)

Fletcher et al-2013-pediatric_blood_&amp;_cancer
Fletcher et al-2013-pediatric_blood_&amp;_cancerFletcher et al-2013-pediatric_blood_&amp;_cancer
Fletcher et al-2013-pediatric_blood_&amp;_cancer
 
Fletcher et al-2013-pediatric_blood_&amp;_cancer
Fletcher et al-2013-pediatric_blood_&amp;_cancerFletcher et al-2013-pediatric_blood_&amp;_cancer
Fletcher et al-2013-pediatric_blood_&amp;_cancer
 
G Js Poster Amda Abstract
G Js Poster Amda AbstractG Js Poster Amda Abstract
G Js Poster Amda Abstract
 
2.1.11template For Nv Slide Show
2.1.11template For Nv Slide Show2.1.11template For Nv Slide Show
2.1.11template For Nv Slide Show
 
Curb 65 thorax-2003-lim-377-82
Curb 65 thorax-2003-lim-377-82Curb 65 thorax-2003-lim-377-82
Curb 65 thorax-2003-lim-377-82
 
An AIDS-Defining Illness Presenting during Acute Retroviral Syndrome: A Case ...
An AIDS-Defining Illness Presenting during Acute Retroviral Syndrome: A Case ...An AIDS-Defining Illness Presenting during Acute Retroviral Syndrome: A Case ...
An AIDS-Defining Illness Presenting during Acute Retroviral Syndrome: A Case ...
 
Start impaact june 7 2011
Start impaact june 7 2011Start impaact june 7 2011
Start impaact june 7 2011
 
Deteriorating Patient with Sepsis: Early Diagnosis and Intervention (2017)
Deteriorating Patient with Sepsis: Early Diagnosis and Intervention (2017)Deteriorating Patient with Sepsis: Early Diagnosis and Intervention (2017)
Deteriorating Patient with Sepsis: Early Diagnosis and Intervention (2017)
 
Applied Epid
Applied EpidApplied Epid
Applied Epid
 
The value of real-world evidence for clinicians and clinical researchers in t...
The value of real-world evidence for clinicians and clinical researchers in t...The value of real-world evidence for clinicians and clinical researchers in t...
The value of real-world evidence for clinicians and clinical researchers in t...
 
04.09.21 | Making Sense of the COVID-19 Data in Persons with HIV
04.09.21 | Making Sense of the COVID-19 Data in Persons with HIV04.09.21 | Making Sense of the COVID-19 Data in Persons with HIV
04.09.21 | Making Sense of the COVID-19 Data in Persons with HIV
 
Presentació resultats Estudi multicèntric amb telemedicina Red Promete per pa...
Presentació resultats Estudi multicèntric amb telemedicina Red Promete per pa...Presentació resultats Estudi multicèntric amb telemedicina Red Promete per pa...
Presentació resultats Estudi multicèntric amb telemedicina Red Promete per pa...
 
Telemedicine: Maintaining The Control and Clinical Outcomes During COVID-19 P...
Telemedicine: Maintaining The Control and Clinical Outcomes During COVID-19 P...Telemedicine: Maintaining The Control and Clinical Outcomes During COVID-19 P...
Telemedicine: Maintaining The Control and Clinical Outcomes During COVID-19 P...
 
Telemedicine: Maintaining The Control and Clinical Outcomes During COVID-19 P...
Telemedicine: Maintaining The Control and Clinical Outcomes During COVID-19 P...Telemedicine: Maintaining The Control and Clinical Outcomes During COVID-19 P...
Telemedicine: Maintaining The Control and Clinical Outcomes During COVID-19 P...
 
Early HIV Intervention by Dr. Rachel Baden
Early HIV Intervention by Dr. Rachel BadenEarly HIV Intervention by Dr. Rachel Baden
Early HIV Intervention by Dr. Rachel Baden
 
Assessing the effects of prognostic factors in recovery of tuberculosis patie...
Assessing the effects of prognostic factors in recovery of tuberculosis patie...Assessing the effects of prognostic factors in recovery of tuberculosis patie...
Assessing the effects of prognostic factors in recovery of tuberculosis patie...
 
Adverse effects of delayed antimicrobial treatment and surgical source contro...
Adverse effects of delayed antimicrobial treatment and surgical source contro...Adverse effects of delayed antimicrobial treatment and surgical source contro...
Adverse effects of delayed antimicrobial treatment and surgical source contro...
 
Risk factors of chronic liver disease amongst patients receiving care in a Ga...
Risk factors of chronic liver disease amongst patients receiving care in a Ga...Risk factors of chronic liver disease amongst patients receiving care in a Ga...
Risk factors of chronic liver disease amongst patients receiving care in a Ga...
 
Four Unique Laboratory Characteristics Applied to Assess the Severity of COVI...
Four Unique Laboratory Characteristics Applied to Assess the Severity of COVI...Four Unique Laboratory Characteristics Applied to Assess the Severity of COVI...
Four Unique Laboratory Characteristics Applied to Assess the Severity of COVI...
 
Four Unique Laboratory Characteristics Applied to Assess the Severity of COVI...
Four Unique Laboratory Characteristics Applied to Assess the Severity of COVI...Four Unique Laboratory Characteristics Applied to Assess the Severity of COVI...
Four Unique Laboratory Characteristics Applied to Assess the Severity of COVI...
 

3.10 Nv Poster Draft

  • 1.